NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC Bulletin Board: ISLT) a clinical stage company engaged in the research, development and commercialization of therapeutics in the field of diabetes, announced today that it was included in the December 27, 2012 issue of BioWorld Today. A link to the full text of the article is below.
"Inclusion in BioWorld is another validation point as this esteemed industry publication recognizes the potential of Islet Sciences," stated John Steel, Islet Sciences Chairman and Chief Executive Officer. "As we continue to make solid progress, it is gratifying to be included in such a well renowned publication."
The link to the article can be found here: http://www.isletsciences.com/BWT122712Islet2.pdf
About Islet Sciences, Inc. Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com
Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.
Islet Sciences Investor Contact: Jeff Ramson ProActive Capital Group (646) 863-6893 email@example.com
SOURCE Islet Sciences, Inc.